Lupin launches generic version of Tamiflu in US
Generics pharma giant Lupin announced the launch of Oseltamivir Phosphate Capsules in the US market. The drugmaker had earlier received USFDA approval for the same.
The company had received approval for Oseltamivir Phosphate Capsules, USP 30 mg (base), 45 mg, and 75 mg. The drug is a generic equivalent of Hoffman-La Roche's Tamiflu. The drug is used for the treatment of acute, uncomplicated influenza A and B in patients. According to IQVIA MAT data, Oseltamivir Phosphate Capsules, USP had annual sales of approximately US$ 518 million in the US
The company has also received tentative USFDA approval for generic Locoid Lotion. Lupin's Hydrocortisone Butyrate Lotion, 0.1% is a generic equivalent of Precision Dermatology's Locoid Lotion, 0.1% used in the topical treatment of mild to moderate atopic dermatitis. The mediation has an annual sales of approximately US$ 16.1 million in the US market.
On Monday, the stock of Lupin closed at Rs. 839.30 per share, up Rs. 18.40 or 2.24 per cent on BSE.